MoonLake Immunotherapeutics (NasdaqCM:MLTX) is back in focus after fresh FDA feedback allowed the company to move ahead with a Biologics License Application for Sonelokimab in hidradenitis suppurativa using existing trial data.

The FDA update has arrived after a volatile stretch for MoonLake, with a 30 day share price return of 25.17% and a 90 day share price return of 79.16%, even as the 1 year total shareholder return sits at a 61.74% loss. This suggests that recent momentum has picked up against a weaker longer term experience for holders.

If this kind of regulatory news has your attention, it may be a good time to scan other healthcare stocks that could offer different risk and return profiles across the sector.

With MoonLake’s shares at US$16.76, recent gains, a 1 year total return decline, zero reported revenue and a price target only about 7% higher, should you see untapped value here or assume the market is already pricing in future growth?

Price to Book of 4.1x: Is It Justified?

At a last close of US$16.76, MoonLake trades on a P/B of 4.1x, which screens as expensive against both its direct peers and the broader US biotech group.

The P/B ratio compares the company’s market value to its net assets on the balance sheet. For a clinical stage biotech with zero reported revenue and ongoing losses, a higher P/B usually reflects market confidence in the value of the pipeline rather than current financial performance.

Here, MoonLake’s P/B of 4.1x sits above the peer average of 3x, and also above the US biotech industry average of 2.6x. That means the market is currently placing a richer valuation on MoonLake’s balance sheet than on the typical peer, even though the company is unprofitable and not forecast to generate revenue or achieve profitability over the next few years.

Result: Price-to-book of 4.1x (OVERVALUED)

However, investors still need to weigh the clinical and regulatory uncertainty around Sonelokimab, as well as the fact that MoonLake currently reports zero revenue and a US$210.50m annual loss.

Build Your Own MoonLake Immunotherapeutics Narrative

If you see this story differently or simply want to test your own view against the data, you can build a customised thesis for MoonLake in just a few minutes, starting with Do it your way.

A great starting point for your MoonLake Immunotherapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If MoonLake has sharpened your focus on healthcare, do not stop there. Broaden your watchlist with other targeted ideas that could suit your style and risk tolerance.

• Spot potential early stage opportunities by scanning these 3529 penny stocks with strong financials that already show stronger balance sheets and fundamentals than many peers.
• Position yourself in fast moving trends by checking out these 24 AI penny stocks that are tied to artificial intelligence themes across different parts of the market.
• Strengthen your income focus by reviewing these 12 dividend stocks with yields > 3% that currently offer yields above 3% and may fit a cash flow oriented approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.